Lixisenatide, a drug developed by Sanofi already used against type 2 diabetes, could slow the progression of Parkinson's motor symptoms. A clinical trial carried out in patients with an early stage of the disease.
Results described as a first although it remains to be confirmed in a larger study. Parkinson's affects around 10 million people worldwide and can prove very disabling in daily life. It results from the progressive disappearance in the brain of neurons producing dopamine, the neurotransmitter that controls motor skills.